BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Öberg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 2016;23:R551-66. [PMID: 27697899 DOI: 10.1530/ERC-16-0151] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer 2018;25:309-22. [PMID: 29330194 DOI: 10.1530/ERC-17-0455] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
2 Grimaldi M, Santoro A, Buonocore M, Crivaro C, Funicello N, Sublimi Saponetti M, Ripoli C, Rodriquez M, De Pasquale S, Bobba F, Ferrazzano L, Cabri W, D’ursi AM, Ricci A. A New Approach to Supramolecular Structure Determination in Pharmaceutical Preparation of Self-Assembling Peptides: A Case Study of Lanreotide Autogel. Pharmaceutics 2022;14:681. [DOI: 10.3390/pharmaceutics14030681] [Reference Citation Analysis]
3 Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 2020;182:583. [PMID: 32217809 DOI: 10.1530/EJE-19-0762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
4 Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Peel A, Blanco-Acevedo C, Solivera J, Ibáñez-Costa A, Gahete MD, Castaño JP, Luque RM. Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. Int J Mol Sci 2022;23:1143. [PMID: 35163067 DOI: 10.3390/ijms23031143] [Reference Citation Analysis]
5 Rodriguez M, Frost JA, Schonbrunn A. Real-Time Signaling Assays Demonstrate Somatostatin Agonist Bias for Ion Channel Regulation in Somatotroph Tumor Cells. J Endocr Soc 2018;2:779-93. [PMID: 30151433 DOI: 10.1210/js.2018-00115] [Reference Citation Analysis]
6 Shi C, Ye Z, Han J, Ye X, Lu W, Ji C, Li Z, Ma Z, Zhang Q, Zhang Y, He W, Chen Z, Cao X, Shou X, Zhou X, Wang Y, Zhang Z, Li Y, Ye H, He M, Chen H, Cheng H, Sun J, Cai J, Huang C, Ye F, Luo C, Zhou B, Ding H, Zhao Y. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neuro Oncol 2020;22:1114-25. [PMID: 32246150 DOI: 10.1093/neuonc/noaa084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 31.0] [Reference Citation Analysis]
8 Nomoto H, Kameda H, Nakamura A, Tsuchida K, Nagai S, Atsumi T, Miyoshi H. Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment. Front Endocrinol (Lausanne) 2019;10:131. [PMID: 30881346 DOI: 10.3389/fendo.2019.00131] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12. [PMID: 28430638 DOI: 10.18632/oncotarget.15684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
10 Cuyle PJ, Prenen H. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. Ann Gastroenterol. 2018;31:140-150. [PMID: 29507461 DOI: 10.20524/aog.2018.0224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, Herrera-Martínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 2022;16:764-79. [PMID: 34601790 DOI: 10.1002/1878-0261.13107] [Reference Citation Analysis]
12 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Catalani E, De Palma C, Perrotta C, Cervia D. Current Evidence for a Role of Neuropeptides in the Regulation of Autophagy. Biomed Res Int 2017;2017:5856071. [PMID: 28593174 DOI: 10.1155/2017/5856071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
14 Liu F, Guo X, Liu T, Xu X, Li N, Xiong C, Li C, Zhu H, Yang Z. Evaluation of Pan-SSTRs Targeted Radioligand [64Cu]NOTA-PA1 Using Micro-PET Imaging in Xenografted Mice. ACS Med Chem Lett 2020;11:445-50. [PMID: 32292548 DOI: 10.1021/acsmedchemlett.9b00544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Streit L, Moog S, Hugel S, Rame M, Tanguy E, Andry V, Schmid HA, Brunaud L, Bihain F, Nominé-Criqui C, Goumon Y, Lacomme S, Lomazzi S, Vix M, Mutter D, Vitale N, Ory S, Gasman S. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells. Cancer Lett 2022;524:232-44. [PMID: 34637845 DOI: 10.1016/j.canlet.2021.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Popielarz-Grygalewicz A, Gąsior JS, Konwicka A, Grygalewicz P, Stelmachowska-Banaś M, Zgliczyński W, Dąbrowski M. Heart in Acromegaly: The Echocardiographic Characteristics of Patients Diagnosed with Acromegaly in Various Stages of the Disease. Int J Endocrinol 2018;2018:6935054. [PMID: 30123265 DOI: 10.1155/2018/6935054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
17 Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, Herrera-Martínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 2022;16:764-79. [PMID: 34601790 DOI: 10.1002/1878-0261.13107] [Reference Citation Analysis]
18 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
19 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Li XN, Rao T, Xu YF, Hu KR, Zhu ZP, Li HF, Kang D, Shao YH, Shen BY, Yin XX, Xie L, Wang GJ, Liang Y. Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury. Acta Pharmacol Sin 2018;39:1373-85. [PMID: 29188801 DOI: 10.1038/aps.2017.159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Peel A, Blanco-Acevedo C, Solivera J, Ibáñez-Costa A, Gahete MD, Castaño JP, Luque RM. Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. Int J Mol Sci 2022;23:1143. [PMID: 35163067 DOI: 10.3390/ijms23031143] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335-42. [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589] [Cited by in Crossref: 967] [Cited by in F6Publishing: 897] [Article Influence: 193.4] [Reference Citation Analysis]
23 Bo Q, Yang F, Li Y, Meng X, Zhang H, Zhou Y, Ling S, Sun D, Lv P, Liu L, Shi P, Tian C. Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues. Cell Discov 2022;8:47. [PMID: 35595746 DOI: 10.1038/s41421-022-00405-2] [Reference Citation Analysis]
24 Vitali E, Palagano E, Schiavone ML, Mantovani G, Sobacchi C, Mazziotti G, Lania A. Direct effects of octreotide on osteoblast cell proliferation and function. J Endocrinol Invest 2022. [PMID: 35020172 DOI: 10.1007/s40618-022-01740-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Andre A, Squittieri N, Patil S. Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study. Endocr Pract 2022:S1530-891X(22)00034-9. [PMID: 35123070 DOI: 10.1016/j.eprac.2022.01.010] [Reference Citation Analysis]
26 AlDallal S. Acromegaly: a challenging condition to diagnose. Int J Gen Med 2018;11:337-43. [PMID: 30197531 DOI: 10.2147/IJGM.S169611] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
27 Gosain R, Gupta M, Roy AM, Strosberg J, Glaser KM, Iyer R. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. Cancers 2022;14:1428. [DOI: 10.3390/cancers14061428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gatto F, Arvigo M, Amarù J, Campana C, Cocchiara F, Graziani G, Bruzzone E, Giusti M, Boschetti M, Ferone D. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 2019;22:89-99. [PMID: 30483918 DOI: 10.1007/s11102-018-0926-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
29 Dehestani B, le Roux CW. The Role of the Small Bowel in Unintentional Weight Loss after Treatment of Upper Gastrointestinal Cancers. J Clin Med 2019;8:E942. [PMID: 31261800 DOI: 10.3390/jcm8070942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J. Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. Neurosurg Rev 2021. [PMID: 33899156 DOI: 10.1007/s10143-021-01552-y] [Reference Citation Analysis]
31 Peculis R, Niedra H, Rovite V. Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives. Cancers (Basel) 2021;13:1395. [PMID: 33808624 DOI: 10.3390/cancers13061395] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Petersenn S, Houchard A, Sert C, Caron PJ; PRIMARYS Study Group. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 2020;23:171-81. [PMID: 31879842 DOI: 10.1007/s11102-019-01020-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
33 Doulou E, Kalomiraki M, Parla A, Thermos K, Chaniotakis NA, Panderi I. Hydrophilic Interaction Liquid Chromatography Coupled with Fluorescence Detection (HILIC-FL) for the Quantitation of Octreotide in Injection Forms. Analytica 2021;2:121-9. [DOI: 10.3390/analytica2040012] [Reference Citation Analysis]
34 Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab 2020;11:2042018820965068. [PMID: 33329885 DOI: 10.1177/2042018820965068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist 2019;24:463-74. [PMID: 30355775 DOI: 10.1634/theoncologist.2018-0217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Shamsi BH, Chatoo M, Xu XK, Xu X, Chen XQ. Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System. Front Endocrinol (Lausanne) 2021;12:652363. [PMID: 33796080 DOI: 10.3389/fendo.2021.652363] [Reference Citation Analysis]
37 Adelman D, Truong Thanh XM, Feuilly M, Houchard A, Cella D. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Adv Ther 2020;37:1608-19. [PMID: 32157626 DOI: 10.1007/s12325-020-01255-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
38 Polowczyk B, Kałużny M, Bolanowski M. Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects. Postepy Hig Med Dosw 2020;74:272-82. [DOI: 10.5604/01.3001.0014.3056] [Reference Citation Analysis]